ABBV-744 是一种首创,具有口服活性和选择性的 BET 家族蛋白 BDII 结构域 (BDII domain),对 BRD2、BRD3、BRD4 和 BRDT 的IC50值为 4~18 nM。ABBV-744 主要由 CYP3A4 代谢,具有类似药物的特性,可用于研究其抗肿瘤功效和耐受性。
生物活性 | ABBV-744 is a first-in-class, orally active and selective inhibitor of theBDII domainof BET family proteins withIC50values ranging from 4 to 18 nM forBRD2,BRD3,BRD4andBRDT. ABBV-744 is primarily metabolized by CYP3A4 with drug-like properties enable the investigation of its antitumor efficacy and tolerability[1]. |
IC50& Target[1] | BRD2 (BD2) 8 nM (IC50) | BRD3 (BD2) 13 nM (IC50) | BRDT (BD2) 18 nM (IC50) | BRD4 (BD2) 4 nM (IC50) | BRD4 (BD2) 3 nM (Kd) |
|
体外研究 (In Vitro) | ABBV-744 (90 nM; 0~24 h; LNCaP cells) downregulates the expression of KLK2 and MYC genes[1]. ABBV-744 (90 nM; 0~72 h; LNCaP cells) induces cell cycle arrest in G1 followed by senescence[1].
Western Blot Analysis[1] Cell Line: | LNCaP cells | Concentration: | 90 nM | Incubation Time: | 0~24 hours | Result: | Downregulated the expression of KLK2 and MYC genes. |
Cell Cycle Analysis[1] Cell Line: | LNCaP cells | Concentration: | 90 nM | Incubation Time: | 0~72 hours | Result: | Induced cell cycle arrest in G1 followed by senescence. |
|
体内研究 (In Vivo) | ABBV-744 (4.7 mg/kg; oral gavage; 28 days) causes a delay in tumor growth and displays equivalent or better antitumor activity compared with ABBV-075[1]. ABBV-744 (30 mg/kg; 14 days) is able to produce significant antitumor activity. ABBV-744 (30 mg/kg) triggers a reduction in platelets of only 20 %[1].
Animal Model: | Mice | Dosage: | 4.7 mg/kg (Pharmacokinetic Analysis) | Administration: | Oral gavage; 28 days | Result: | Caused a delay in tumor growth and displayed equivalent or better antitumor activity compared with ABBV-075. |
Animal Model: | Sprague-Dawley rats | Dosage: | 30 mg/kg (Pharmacokinetic Analysis) | Administration: | 14 days | Result: | Produced significant antitumor activity. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
溶解性数据 | In Vitro: DMSO : 100 mg/mL(203.44 mM;Need ultrasonic) 配制储备液 1 mM | 2.0344 mL | 10.1719 mL | 20.3438 mL | 5 mM | 0.4069 mL | 2.0344 mL | 4.0688 mL | 10 mM | 0.2034 mL | 1.0172 mL | 2.0344 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (stored under nitrogen)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.09 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.09 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.09 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 4. 请依序添加每种溶剂: 50%PEG300 50% saline Solubility: 2.5 mg/mL (5.09 mM); Suspended solution; Need ultrasonic 5. 请依序添加每种溶剂: 5% DMSO 40%PEG300 5%Tween-80 50% saline Solubility: ≥ 2 mg/mL (4.07 mM); Clear solution 6. 请依序添加每种溶剂: 5% DMSO 95% (20%SBE-β-CDin saline) Solubility: ≥ 2 mg/mL (4.07 mM); Clear solution *以上所有助溶剂都可在本网站选购。
|